Stay updated with breaking news from Guy Braunstein. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland - October 11, 2021Idorsia Ltd (SIX: IDIA) today announced that MODIFY, the Phase 3 study to investigate the effect of lucerastat, as
Classical CDs: wolves, woodwinds and a masonic funeral | reviews, news & interviews Classical CDs: wolves, woodwinds and a masonic funeral Classical CDs: wolves, woodwinds and a masonic funeral A great pianist celebrates a significant birthday, plus music for solo winds and a rare French ballet score by Graham RicksonSaturday, 17 July 2021 Martha Argerich Edition (EuroArts) Almost eight hours of Martha Argerich on film. What a glorious prospect! This six-DVD set mostly consists of recordings of live concerts. The set was released to celebrate the great Argentinian’s 80th birth...
Idorsia Pharmaceuticals Ltd: Idorsia initiates the Phase 3 registration study with selatogrel for the treatment of acute myocardial infarction Idorsia to host an investor webcast to discuss the Phase 3 study today at 14:30hrs CEST Allschwil, Switzerland - June 2 , 2021 Idorsia Ltd (SIX: IDIA) today announced the initiation of the Phase 3 registration study "SOS-AMI" to evaluate the efficacy and safety of self-administered subcutaneous selatogrel, Idorsia's P2Y 12 receptor antagonist, in suspected acute myocardial infarction (AMI). An AMI, or heart attack, is a life-threatening condition that ...
Press release content from Globe Newswire. The AP news staff was not involved in its creation. Idorsia initiates the Phase 3 registration study with selatogrel for the treatment of acute ... Idorsia Pharmaceuticals LtdJune 28, 2021 GMT Ad hoc announcement pursuant to Art. 53 LR Idorsia to host an investor webcast to discuss the Phase 3 study today at 14:30hrs CEST Allschwil, Switzerland – June 28, 2021 Idorsia Ltd (SIX: IDIA) today announced the initiation of the Phase 3 registration study “SOS-AMI” to evaluate the efficacy and safety of self-administered subcutaneous selatogrel, I...
and Chair of the Steering Committee for SOS-AMI, commented: "P2Y 12 receptor antagonists have been used in the treatment of millions of patients globally, and their safety and efficacy profiles are well established. Despite the success of chronic treatment with this class and other effective interventions, patients are still suffering recurrent heart attacks. The idea for patients to self-inject early in the onset of symptoms is truly innovative. The subcutaneous route of administration could overcome the onset delay observed with oral compounds from the same class." To be effective, any ant...